Jake Brockmeyer

Dr. Jake Brockmeyer

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2020 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
JBJake Brockmeyer
Jake Brockmeyer
RWRussell T. Wise
Russell T. Wise
EBElizabeth Burgener
Elizabeth Burgener
CMCarlos Milla
Carlos Milla
AFAdam Frymoyer
Adam Frymoyer

8 November 2024 in Clinical Transplantation
Verified
Journal Article
Closed access
EWErica Wong
Erica Wong
JBJake Brockmeyer
Jake Brockmeyer
CBChristian Benden
Christian Benden
NANicholas Avdimiretz
Nicholas Avdimiretz

14 January 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JBJake Brockmeyer
Jake Brockmeyer
LBLaura Bio
Laura Bio
CMCarlos Milla
Carlos Milla
AFAdam Frymoyer
Adam Frymoyer
Background: Tobramycin is a key therapy for pulmonary exacerbations in children and adolescents with cystic fibrosis (CF), yet its variable pharmacokinetics (PK) combined with narrow therapeutic index necessitates therapeutic drug monitoring (TDM) during clinical care to optimize exposure while minimizing toxicity. Model-informed precision dosing (MIPD) is a potentially powerful tool to support dose individualization in clinical care that leverages population PK models and Bayesian forecasting. Herein, we evaluated the performance of an MIPD initiative at our hospital for once-daily tobramycin in pediatric patients with CF. Methods: Tobramycin practices at a single CF center before (2016–2018) and after (2019–2025) implementation of an MIPD initiative in CF patients < 21 years were evaluated. TDM during the pre-MIPD period used traditional log-linear AUC calculations, while the post-MIPD period used a commercial MIPD software platform integrated within the electronic health record. Outcomes included attainment of the target 24 h area-under-the-curve (AUC24 80–120 mg·h/L), number of TDM samples and dose adjustments during the first 7 days of treatment, and rates of acute kidney injury (AKI). Results: A total of 114 treatment courses were analyzed (77 pre-MIPD, 37 post-MIPD). Post-MIPD target attainment was 75.7% at TDM1, 89.2% at TDM2, and 100% at TDM3, significantly higher than pre-MIPD at corresponding cycles. The post-MIPD period required fewer TDM samples (4.2 vs. 7.1; p < 0.001) and dose adjustments (0.7 vs. 1.8; p < 0.001) in the first 7 days. AKI incidence remained low and comparable between periods. Conclusions: Implementation of an MIPD initiative for tobramycin in pediatric patients with CF led to the early attainment of therapeutic AUC24 targets while reducing TDM burden and dose adjustments.